Make sterile connections faster, easier and safer with genderless connectors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Make sterile connections faster, easier and safer with genderless connectors

Genderless AseptiQuik® G sterile connectors from CPC simplify single-use systems design and process integration. Our innovative design eliminates separate male and female components to substantially reduce complexity and support modular system design. Because the connectors are interchangeable—any single-use G series connector mates with any other G series connector—systems are more flexible and minimize supply chain complexity.

G series connectors are available in a full range of interchangeable 6.4 mm to 19.0 mm (1/4” to 3/4”) flow solutions, in both gamma and high-temperature versions. Terminations include 6.4 mm to 19.0 mm hose barb and 19.0 mm mini-sanitary.

The G series is part of the AseptiQuik family which offers the broadest range of single-use sterile connectors in the industry with flow configurations from 3.2 mm to 25.4 mm (1/8” to 1”). AseptiQuik connectors provide ease-of-use, robust construction and reliable performance for transferring valuable media. AseptiQuik’s are ideal for single-bag and tubing assemblies,cell banking, bioreactors, mixers,
sampling, formulation and filling applications.

See how the G series works AseptiQuik G video

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here